Landscape Capital Management, L.L.C. Akebia Therapeutics, Inc. Transaction History

Landscape Capital Management, L.L.C.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $216,589 - $349,505	-40,035 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $215,788 - $366,320	40,035 New	40,035 $221,000
Q3 2018 Nov 14, 2018	SELL	$7.44 - $10.65 $542,219 - $776,161	-72,879 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $398,363 - $493,709	-43,537 Reduced 37.4%	72,879 $727,000
Q1 2018 May 11, 2018	BUY	$9.53 - $15.68 $784,461 - $1.29 Million	82,315 Added 241.39%	116,416 $1.11 Million
Q4 2017 Feb 13, 2018	BUY	$14.24 - $19.59 $281,311 - $387,000	19,755 Added 137.7%	34,101 $507,000
Q3 2017 Nov 14, 2017	SELL	$13.06 - $19.67 $153,024 - $230,473	-11,717 Reduced 44.96%	14,346 $282,000
Q2 2017 Aug 14, 2017	BUY	N/A	26,063	26,063 $375,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $329M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Landscape Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Landscape Capital Management, L.L.C. with notifications on news.